Obsidian lands $160M Series C —but IPO still in the cards

Obsidian Therapeutics Inc. once had its sights set on an initial public offering by early 2023. But then the market turned. Now, CEO Madan Jagasia explains the company's new Series C round and plans to enter the public market.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news